Loading
Elypta
Elypta, of Stockholm, measures glycosaminoglycans, sugar molecules in blood and urine, and scores them with machine learning to detect kidney cancer returning after surgery; a second programme tests whether the same signature can flag any cancer early in symptom-free adults. Only interim data support the screening use.
Overview
Elypta, based in Solna, Stockholm, has developed a metabolism-based liquid biopsy that profiles the glycosaminoglycan (GAG) composition of blood and urine (the GAGome), using its MIRAM kit and machine-learning scores to detect cancer-specific signatures; the company is ISO 13485 certified. Its first application is recurrence monitoring after kidney cancer surgery: the AURORAX programme, described as the largest such study, reached study end in May 2025. A second programme applies GAGome scores to multi-cancer early detection in asymptomatic adults, with interim data suggesting urine GAGs may predict risk of any cancer. Funding includes a EUR 2.35 million Horizon 2020 grant (2019), a EUR 6.1 million late seed led by Industrifonden (2020), a $21 million Series A led by Bonnier Ventures (2022) and a $1 million Roddenberry prize (2023).
Headquarters
Stockholm, SE
Scorecard
All companies#502of 1520 companies, score 2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Led by Bonnier Ventures, June 2022. | 2022 | $21M | elypta.com |
| Seed · EUR 6.1 million late seed round led by Industrifonden, January 2020 (as listed on the company news page). | 2020 | undisclosed | elypta.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1EmergingMulti-cancer early detection test in development (urine and plasma glycosaminoglycans)
Elypta GAGome multi-cancer test · GAGome
A test in development from Elypta in Sweden that reads sugar molecules in urine and blood rather than DNA, aiming to flag many cancers including some that DNA tests find hard to see.
Notes
- Founding year not stated (earliest news item is July 2017). The Horizon 2020 grant and Roddenberry prize are described on the news listing page but not recorded as rounds because their individual pages were not fetched.
Key papers
1Connected
10Similar pages
- TreatmentAminoIndex Cancer Screening (AICS)
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- TreatmentCancer Differentiation Analysis (CDA)
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- TrialPlasma metabolite markers for 13 cancers (Beijing Friendship Hospital)
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- TrialEMERALD (EXoPERT extracellular vesicle Raman test)
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- TrialJinling Cohort (MERCURY multi-omic test in Nanjing)
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- TrialMETHYLSCAPE-CO (Methylscape test in body fluids, Colombia)
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- TrialNQMD-CS (five-cancer methylation test in a screening population, Guangzhou)
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- TrialPROFOUND (Weihe multi-omic multi-cancer case-control study)
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
cancers
fronts
technologies
drugs
EmergingMulti-cancer early detection test in development (urine and plasma glycosaminoglycans)
Elypta GAGome multi-cancer test · GAGome
trials
key papers
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/